These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 16393327

  • 1. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge.
    Erin EM, Zacharasiewicz AS, Nicholson GC, Tan AJ, Higgins LA, Williams TJ, Murdoch RD, Durham SR, Barnes PJ, Hansel TT.
    Clin Exp Allergy; 2005 Dec; 35(12):1608-14. PubMed ID: 16393327
    [Abstract] [Full Text] [Related]

  • 2. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis.
    Weido AJ, Reece LM, Alam R, Cook CK, Sim TC.
    Ann Allergy Asthma Immunol; 1996 Nov; 77(5):407-15. PubMed ID: 8933780
    [Abstract] [Full Text] [Related]

  • 3. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis.
    Masuyama K, Jacobson MR, Rak S, Meng Q, Sudderick RM, Kay AB, Lowhagen O, Hamid Q, Durham SR.
    Immunology; 1994 Jun; 82(2):192-9. PubMed ID: 7927488
    [Abstract] [Full Text] [Related]

  • 4. Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: effects of single allergen challenge.
    Holm A, Dijkstra M, Kleinjan A, Severijnen LA, Boks S, Mulder P, Fokkens W.
    J Allergy Clin Immunol; 2001 Apr; 107(4):627-33. PubMed ID: 11295650
    [Abstract] [Full Text] [Related]

  • 5. Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge.
    Erin EM, Leaker BR, Zacharasiewicz AS, Higgins LA, Williams TJ, Boyce MJ, de Boer P, Durham SR, Barnes PJ, Hansel TT.
    Allergy; 2005 Dec; 60(12):1524-9. PubMed ID: 16266385
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages.
    Gosset P, Tillie-Leblond I, Malaquin F, Durieu J, Wallaert B, Tonnel AB.
    Clin Exp Allergy; 1997 Apr; 27(4):379-88. PubMed ID: 9146930
    [Abstract] [Full Text] [Related]

  • 7. IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy.
    Ghaffar O, Laberge S, Jacobson MR, Lowhagen O, Rak S, Durham SR, Hamid Q.
    Am J Respir Cell Mol Biol; 1997 Jul; 17(1):17-24. PubMed ID: 9224205
    [Abstract] [Full Text] [Related]

  • 8. Increased number of CD34+ cells in nasal mucosa of allergic rhinitis patients: inhibition by a local corticosteroid.
    Sergejeva S, Malmhäll C, Lötvall J, Pullerits T.
    Clin Exp Allergy; 2005 Jan; 35(1):34-8. PubMed ID: 15649263
    [Abstract] [Full Text] [Related]

  • 9. Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge.
    Diaz-Sanchez D, Tsien A, Fleming J, Saxon A.
    Clin Immunol; 1999 Mar; 90(3):313-22. PubMed ID: 10075860
    [Abstract] [Full Text] [Related]

  • 10. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid.
    Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH.
    Am J Respir Crit Care Med; 1995 Jun; 151(6):1900-6. PubMed ID: 7767538
    [Abstract] [Full Text] [Related]

  • 11. Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis.
    Pullerits T, Lindén A, Malmhäll C, Lötvall J.
    Allergy; 2001 Sep; 56(9):871-7. PubMed ID: 11551252
    [Abstract] [Full Text] [Related]

  • 12. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge.
    Wagenmann M, Schumacher L, Bachert C.
    Allergy; 2005 Sep; 60(9):1132-8. PubMed ID: 16076297
    [Abstract] [Full Text] [Related]

  • 13. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study.
    Rimmer J, Peake HL, Santos CM, Lean M, Bardin P, Robson R, Haumann B, Loehrer F, Handel ML.
    Clin Exp Allergy; 2007 Jan; 37(1):8-14. PubMed ID: 17210036
    [Abstract] [Full Text] [Related]

  • 14. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge.
    Rak S, Jacobson MR, Sudderick RM, Masuyama K, Juliusson S, Kay AB, Hamid Q, Löwhagen O, Durham SR.
    Clin Exp Allergy; 1994 Oct; 24(10):930-9. PubMed ID: 7842362
    [Abstract] [Full Text] [Related]

  • 15. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-gamma, IL-1beta, TNF-alpha, or neutrophils.
    Benson M, Strannegård IL, Strannegård O, Wennergren G.
    J Allergy Clin Immunol; 2000 Aug; 106(2):307-12. PubMed ID: 10932075
    [Abstract] [Full Text] [Related]

  • 16. Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids.
    Masuyama K, Till SJ, Jacobson MR, Kamil A, Cameron L, Juliusson S, Lowhagen O, Kay AB, Hamid QA, Durham SR.
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):610-7. PubMed ID: 9802369
    [Abstract] [Full Text] [Related]

  • 17. Effects of pollen and nasal glucocorticoid on FOXP3+, GATA-3+ and T-bet+ cells in allergic rhinitis.
    Malmhäll C, Bossios A, Pullerits T, Lötvall J.
    Allergy; 2007 Sep; 62(9):1007-13. PubMed ID: 17686103
    [Abstract] [Full Text] [Related]

  • 18. Interleukin 17 and RANTES levels in induced sputum of patients with allergic rhinitis after a single nasal allergen challenge.
    Semik-Orzech A, Barczyk A, Wiaderkiewicz R, Pierzchala W.
    Ann Allergy Asthma Immunol; 2009 Nov; 103(5):418-24. PubMed ID: 19927541
    [Abstract] [Full Text] [Related]

  • 19. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.
    Wilson DR, Nouri-Aria KT, Walker SM, Pajno GB, O'Brien F, Jacobson MR, Mackay IS, Durham SR.
    J Allergy Clin Immunol; 2001 Jun; 107(6):971-6. PubMed ID: 11398073
    [Abstract] [Full Text] [Related]

  • 20. Factors contributing to nasal allergic late phase eosinophilia.
    Kramer MF, Jordan TR, Klemens C, Hilgert E, Hempel JM, Pfrogner E, Rasp G.
    Am J Otolaryngol; 2006 Jun; 27(3):190-9. PubMed ID: 16647984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.